0
lives studied
0
articles
1. Saxenda ® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of ≥30 kg/m2 (obese) or BMI ≥27 kg/m2 (overweight) in the presence of at least one weight-related co-morbid condition (e.g., hypertension, type 2 diabetes, or dyslipidemia).
2. Health Economics & Outcomes Research
3. Saxenda® is not indicated for treatment of Type 2 Diabetes.
4. Victoza®, Ozempic®, Xultophy® 100/3.6 and Tresiba® are not indicated for chronic weight management.
Sort our evidence library by
evidence type,
product and
category. Select your areas of interest, view your results.
View Articles
- PI Prescribing Information Study
- RWE Real World Evidence
- HE Health Economic Data